Prader-Willi Syndrome

Clinical Trial Title An Observational Study of VYKAT™ XR (Diazoxide Choline Extended-Release Tablets) in Patients with Prader-Willi Syndrome (PWS)
Trial Status Open to Enrollment
Start Date 02/24/2026
Location Randall Children's Diabetes and Endocrine Program
Trial Type Pediatric Endocrinology
Specific Condition Prader-Willi Syndrome
Description Prospective observational study developed to generate more evidence of the safety profile, clinical characteristics and outcomes of patients with PWS treated with VYKAT XR.
Eligibility Criteria

Eligibility Criteria

  • Patients currently receiving or initiating treatment with VYKAT XR, including patients who previously received DCCR or are transitioning from DCCR to VYKAT XR in the context of a prior DCCR clinical trial.
  • Patients and/or caregivers must provide written informed consent.
IRB Number 10916
Notes Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
Principal Investigator Maya Hunter, MD
Contact Name Brenna Bogle
Contact Phone 503-413-3508
Contact Fax 503-413-3543
Contact E-Mail bbogle@lhs.org